Genmab A (GMAB) Operating Expenses (2018 - 2026)

Genmab A (GMAB) has reported Operating Expenses for 9 consecutive years, with -$780.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 28.57% year-over-year to -$780.0 million; the trailing twelve-month figure through Jun 2026 stood at -$4.2 billion (up 20.0% YoY), and the FY2025 full-year result was -$2.7 billion, down 23.55% from the prior year.
• Operating Expenses fell to -$780.0 million in Q2 2026 per GMAB's latest filing, from -$716.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at -$195.2 million in Q2 2022 and bottomed at -$2.9 billion in Q3 2023.
• Historically, Operating Expenses has averaged -$1.2 billion across 5 years, with a median of -$1.0 billion in 2024.
• The widest YoY moves for Operating Expenses: up 47.52% in 2024, down 300.95% in 2024.
• Over 5 years, Operating Expenses stood at -$195.2 million in 2022, then plunged by 728.8% to -$1.6 billion in 2023, then sank by 32.82% to -$2.1 billion in 2024, then climbed by 22.99% to -$1.7 billion in 2025, then soared by 52.87% to -$780.0 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered -$780.0 million, -$716.0 million, and -$1.7 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.